UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma

Journal of clinical oncology, 1996-07, Vol.14 (7), p.2083-2090

1996

Volltextzugriff (PDF)

Variation in breast cancer surgery in Ontario

Canadian Medical Association journal, 1994-02, Vol.150 (3), p.345

1994

Volltextzugriff (PDF)

MIB-1 Proliferative Activity Is a Significant Prognostic Factor in Primary Thick Cutaneous Melanomas

Journal of investigative dermatology, 1995-07, Vol.105 (1), p.22-26

1995

Volltextzugriff (PDF)

Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer

Canadian Medical Association journal, 1999-01, Vol.160 (1), p.70

1999

Volltextzugriff (PDF)

Extragonadal germ cell tumors. A 14‐year Toronto experience

Cancer, 1994-04, Vol.73 (7), p.1971-1979

1994

Volltextzugriff (PDF)

We may get this horse to water, but will it drink?

Canadian Medical Association journal (CMAJ), 1998-02, Vol.158 (3), p.345

Iscoe, N A

1998

Volltextzugriff (PDF)

Prostate cancer screening: waiting for Godot

Canadian Medical Association journal (CMAJ), 1998-12, Vol.159 (11), p.1375

Iscoe, N A

1998

Volltextzugriff (PDF)

Prostate cancer: 1. The descriptive epidemiology in Canada

Canadian Medical Association journal, 1998-09, Vol.159 (5), p.509

1998

Volltextzugriff (PDF)

Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference?

Canadian Medical Association journal, 1994-04, Vol.150 (7), p.1109

1994

Volltextzugriff (PDF)

Prostate Cancer Screening in the Midst of Controversy: Canadian Men's Knowledge, Beliefs, Utilization, and Future Intentions

Canadian journal of public health, 1997-09, Vol.88 (5), p.327-332

1997

Volltextzugriff (PDF)

Free-standing health care facilities: financial arrangements, quality assurance and a pilot study

Canadian Medical Association journal, 1998-02, Vol.158 (3), p.359

1998

Volltextzugriff (PDF)

The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma

British journal of surgery, 1985-08, Vol.72 (8), p.614-617

1985

Volltextzugriff (PDF)

A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

Annals of oncology, 1993-03, Vol.4 (3), p.254-255

1993

Volltextzugriff (PDF)

Trends in Hormonal Management of Prostate Cancer: A Population-Based Study in Ontario

Medical care, 2001-04, Vol.39 (4), p.384-396

2001

Volltextzugriff (PDF)

Prostate cancer: 10. Palliative care

Canadian Medical Association journal (CMAJ), 1999-02, Vol.160 (3), p.365

1999

Volltextzugriff (PDF)

A double-blind, randomized, prospective, phase II trial of capecitabine (Cap) plus enzastaurin (Enz) versus cap plus placebo in patients (pts) with advanced breast cancer (BrCa) and prior anthracycline and taxane treatment

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1054-1054

2010

Volltextzugriff (PDF)

Observer error in the characterization of hepatic lesions in patients with neoplastic liver disease

Journal of clinical ultrasound, 1988-10, Vol.16 (8), p.577-579

1988

Volltextzugriff (PDF)

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 1996-07, Vol.14 (7), p.2083-2090

1996

Volltextzugriff (PDF)

Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study

Investigational new drugs, 1990-02, Vol.8 (1), p.121-123

1990

Volltextzugriff (PDF)

A phase II study of weekly edatreate (10-EDAM) in metastatic melanoma: a national cancer institute of Canada clinical trials groups study

Annals of oncology, 1993, Vol.4 (3), p.254-255

1993

Volltextzugriff (PDF)

Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials

European journal of cancer (1990), 2022-07, Vol.169, p.74-81

2022

Volltextzugriff (PDF)

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma

Cancer, 2006-04, Vol.106 (7), p.1431-1442

2006

Volltextzugriff (PDF)

Fat oxidation rate and the exercise intensity that elicits maximal fat oxidation decreases with pubertal status in young male subjects

Journal of applied physiology (1985), 2008-08, Vol.105 (2), p.742-748

2008

Volltextzugriff (PDF)

207 Evaluation of EHR-Integrated Clinical Pathway Implementation of High Sensitivity Troponin Upon Emergency Department Disposition Rates

Annals of emergency medicine, 2023-10, Vol.82 (4), p.S94

2023

Volltextzugriff (PDF)

210 Electronic Health Record-Integrated Clinical Pathway and Transition to High Sensitivity Troponin to Promote Standardization of Attending Physician Chest Pain Care

Annals of emergency medicine, 2023-10, Vol.82 (4), p.S95-S96

2023

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Humans
(38)
Life Sciences & Biomedicine
(36)
Male
(22)
Middle Aged
(20)
Female
(19)
Aged
(18)
Biological And Medical Sciences
(18)
Adult
(17)
Medical Sciences
(16)
Oncology
(14)
General & Internal Medicine
(12)
Medicine, General & Internal
(12)
Cancer
(7)
Antineoplastic Agents
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Melanoma - Drug Therapy
(6)
Melanoma - Pathology
(6)
Pharmacology. Drug Treatments
(6)
Skin Neoplasms - Pathology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma

Variation in breast cancer surgery in Ontario

MIB-1 Proliferative Activity Is a Significant Prognostic Factor in Primary Thick Cutaneous Melanomas

Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer

Extragonadal germ cell tumors. A 14‐year Toronto experience

We may get this horse to water, but will it drink?

Prostate cancer screening: waiting for Godot

Prostate cancer: 1. The descriptive epidemiology in Canada

Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference?

Prostate Cancer Screening in the Midst of Controversy: Canadian Men's Knowledge, Beliefs, Utilization, and Future Intentions

Free-standing health care facilities: financial arrangements, quality assurance and a pilot study

The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma

A phase II study of weekly Edatrexate (10-EDAM) in metastatic melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

Trends in Hormonal Management of Prostate Cancer: A Population-Based Study in Ontario

Prostate cancer: 10. Palliative care

A double-blind, randomized, prospective, phase II trial of capecitabine (Cap) plus enzastaurin (Enz) versus cap plus placebo in patients (pts) with advanced breast cancer (BrCa) and prior anthracycline and taxane treatment

Observer error in the characterization of hepatic lesions in patients with neoplastic liver disease

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group

Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study

A phase II study of weekly edatreate (10-EDAM) in metastatic melanoma: a national cancer institute of Canada clinical trials groups study

Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma

Fat oxidation rate and the exercise intensity that elicits maximal fat oxidation decreases with pubertal status in young male subjects

207 Evaluation of EHR-Integrated Clinical Pathway Implementation of High Sensitivity Troponin Upon Emergency Department Disposition Rates

210 Electronic Health Record-Integrated Clinical Pathway and Transition to High Sensitivity Troponin to Promote Standardization of Attending Physician Chest Pain Care

Suchergebnisse filtern